Zafgen to Present at the Wedbush PacGrow Healthcare Conference
August 08 2018 - 4:05PM
Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical
company leveraging its proprietary knowledge of MetAP2 systems
biology to develop novel therapies for patients affected by a range
of metabolic diseases, announced today that Jeffrey Hatfield, Chief
Executive Officer of Zafgen, Inc. will present a company overview
at the Wedbush PacGrow Healthcare Conference on Wednesday, August
15, 2018 at 10:55 a.m. ET.
A live audio webcast and replay of the presentation will be
available through the Events and Presentations page of the
Investors section of the Company's website (www.zafgen.com) for 90
days following the conclusion of the live event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical
company leveraging its proprietary MetAP2 biology platform to
develop novel therapies for patients affected by complex metabolic
diseases. Zafgen has pioneered the study of MetAP2 inhibitors in
both common and rare metabolic disorders and is currently advancing
programs for type 2 diabetes, Prader-Willi syndrome and liver
diseases. The Company’s lead product candidate, ZGN-1061, a MetAP2
inhibitor for difficult-to-control type 2 diabetes, has
successfully completed the initial part of a Phase 2 clinical
trial. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:Zafgen, Inc.
Patricia Allen Chief Financial Officer 617-648-9792
MediaKrystle GibbsTen Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
InvestorsJohn WoolfordWestwicke
Partnersjohn.woolford@westwicke.com 443-213-0506
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zafgen (NASDAQ:ZFGN)
Historical Stock Chart
From Apr 2023 to Apr 2024